Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-02-24 00:00:00 ET · period of report 2023-02-22 · accession 0001883850-23-000050 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2023-02-24 | 2023-01-04 | REGN | VAGELOS P ROY | Dir | G - Gift | $0.00 | -291 | 125.8K | -0.2% | $0 |
| D | 2023-02-24 | 2023-02-22 | REGN | VAGELOS P ROY | Dir | F - Tax | $750.16 | -29.0K | 337.6K | -8% | -$21.76M |
| D | 2023-02-24 | 2023-02-22 | REGN | VAGELOS P ROY | Dir | M - OptEx | $270.43 | +42.5K | 366.6K | +13% | +$11.49M |
| D | 2023-02-24 | 2023-02-22 | REGN | VAGELOS P ROY | Dir | M - OptEx | $0.00 | -42.5K | 85.0K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-04 | G | D | 291 | $0.00 | 125,752 | I | — | — | |
| 2 | Common | Common Stock | 2023-02-22 | F | D | 29,005 | $750.16 | 337,578 | D | — | — | |
| 3 | Common | Common Stock | 2023-02-22 | M | A | 42,500 | $270.43 | 366,583 | D by CLAT | — | — | |
| 4 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-02-22 | M | D | 42,500 | $0.00 | 85,000 | D | $270.43 · — to 2023-12-13 | 42,500 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |